Abstract. has been recently demonstrated to participate in the differentiation and development of immune cells, including natural killer cells and B and T lymphocytes, and myeloid linages, including erythroid and megakaryocytic cells. The aberrant expression of miR-181, particularly low expression levels, has been observed in a number of leukemia types, including B-cell chronic lymphocytic leukemia and cytogenetically abnormal acute myeloid leukemia. However, the expression and function of miR-181 in chronic myeloid leukemia (CML) remains unknown. In the present study, the aberrant expression of miR-181a was analyzed in a patient with CML and in the CML K562 cell line. In addition, the function and potential mechanisms of miR-181a in K562 cells with regard to their chemotherapeutic sensitivity to imatinib were investigated. The expression levels of miR-181a were significantly reduced in the patient with CML and in the CML K562 cell line. Furthermore, the overexpression of miR-181a in the K562 cells enhanced the chemotherapeutic sensitivity of these cells to imatinib. The potential mechanism mediating these effects may be associated with the capacity of miR-181a to inhibit cell growth and/or to induce cells apoptosis and differentiation in K562 cells. The results of the present study suggested that miR-181a may be a target for the treatment of CML and a useful indicator of the therapeutic sensitivity of CML to imatinib.
Introduction
MicroRNAs (miRNAs/miRs) are a novel class of regulatory molecules that function mainly at the post-transcriptional level by modulating the expression of their target genes. miRNAs are generated by stepwise cleavage of their genome-encoded transcripts via the RNase Ш enzymes Drosha and Dicer. In this process, one strand of the double-stranded-RNA cleavage products is incorporated into the active ribonucleoprotein complex known as the RNA-induced silencing complex, which results in the degradation of the target mRNA, and/or the repression of its translation (1, 2) .
Previous studies have reported that miRNAs are involved in hematopoiesis and leukemogenesis. Chen et al (3) first identified the preferential expression of miR-181 in B-lymphoid cells of the bone marrow in mice. The study observed that the ectopic expression of miR-181 in hematopoietic stem/progenitor cells led to an increase of B-lineage cells in tissue-culture differentiation assays and in adult mice (3) . Previous studies demonstrated that miR-181a promoted the ontogenesis, differentiation and development of natural killer cells, and was also critical for the development and selection of T lymphocytes (4) (5) (6) (7) (8) . Choong et al (9) noted that the expression of miR-181a was upregulated during the primary stage of erythropoiesis in umbilical cord blood-derived cluster of differentiation (CD)34 + cells. A recent study by Li et al (10) demonstrated that miR-181 acted as a critical molecular switch MicroRNA-181a enhances the chemotherapeutic sensitivity of chronic myeloid leukemia to imatinib for megakaryocytic hematopoiesis by interrupting the Lin28 and let-7 feedback circuit. Additionally, Pekarsky et al (11) identified the aberrant expression of miR-181 in leukemia. In the study, it was observed that the expression levels of miR-181 in B-cell chronic lymphocytic leukemia (B-CLL) were inversely correlated with those of Tcl1, and that the expression of Tcl1 was regulated by miR-181. Calin et al (12) further demonstrated that the high expression levels of the oncogene Tcl1 in patients with B-CLL were due to the low expression levels of miR-181 and miR-29 detected in these patients, which resulted in the pathogenesis of the aggressive form of B-CLL displayed by these patients. Previous studies reported that the upregulation of the miR-181 family was one of the high-risk molecular factors involved in the development of cytogenetically normal acute myeloid leukemia (CN-AML), while the downregulation of miR-181 was associated with an adverse prognosis in patients with cytogenetically abnormal AML (13, 14) .
To date, the role and aberrant expression pattern of miR-181 in CML remain unknown. In the present study, the potential alterations in the expression pattern of miR-181a were evaluated in a patient with CML and in the CML K562 cell line. Furthermore, the function and potential mechanism of miR-181a in mediating the chemotherapeutic sensitivity of K562 cells to the therapeutic drug imatinib were also investigated.
Materials and methods
Blood samples. A patient with CML, diagnosed at The Second Affiliated Hospital of Harbin Medical University (Harbin, Heilongjiang, China), and 3 healthy volunteers, who were used as controls, were recruited for the present study. Once informed consent had been obtained from all the participants in the study, whole blood was collected, and mononuclear cells were isolated by density gradient with Percoll (density, 1.077 g/ml; Amersham Pharmacia Biotech Europe GmbH, Munich, Germany), according to the manufacturer's instructions. The present study was approved by the Ethics Committee of Harbin Medical University.
Cell culture. The CML K562 cell line was acquired from the Institute of Basic Medical Science (Chinese Academy of Medical Science, Beijing, China), while the 293T/17 cell line used for lentivirus packaging was purchased from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco Life Technologies, Beijing, China) containing 10% (v/v) fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 µg/ml), and incubated at 37˚C in the presence of 5% CO 2 .
miR-181a overexpression, lentiviral vector construction, virus packaging and cell infection. The hsa-miR-181a gene was amplified from the genomic DNA of normal human leukocytes by polymerase chain reaction (PCR), using the primers listed in Table I . The amplified hsa-miR-181a gene was sequenced by Genewiz company (Beijing, China) and digested with BamHI (New England Biolabs, Inc., Ipswich, MA, USA, prior to be cloned into the pC-1 plasmid (Addgene, Inc., Cambridge, MA, USA), which was linearized as previously described (10) . Next, the lentiviral vectors were packaged with a lentiviral vector packaging kit (System Biosciences, Mountain View, CA, USA), according to the manufacturer's instructions. K562 cells (1x10 5 ) were plated into each well of a 24-well plate, and 10µl of 1x10 8 IU/ml miR-181a and enhanced green fluorescent protein (EGFP) lentiviral vectors were added into 24-well plate and incubated for 12 h, respectively. Subsequently, lentiviral vector-infected K562 cells were transferred to a 25 cm 2 flask and grown for at least 72 h prior to be sorted using a FACSAria II cell sorter (BD Biosciences, Franklin Lakes, NJ, USA). The purified lentiviral vectors infected K562 cells were denoted as K562-miR-181a and K562-EGFP, respectively.
RNA isolation and reverse transcription-quantitative PCR (RT-qPCR).
Total RNA was extracted from the harvested cells using TRIzol (Invitrogen Life Technologies, Carlsbad, CA, USA), and quantified using the absorbance at 260 nm. cDNA was synthesized from 2 µg of total RNA with M-MLV reverse transcriptase (Invitrogen Life Technologies). Oligo(dT) 18 and stem-loop primers were used as primers for the RT of mRNAs and miRNAs, respectively. RT-qPCR was performed with a Bio-Rad Real-Time PCR System (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using a SYBR Premix Ex Taq kit (Takara Biotechnology Co., Ltd., Dalian, China), according to the manufacturer's instructions. The relative expression levels of the genes of interest were analyzed by the 2 -∆∆Ct method. GAPDH and U6 were used as endogenous controls for the quantification of mRNA and miRNA, respectively. The sequence of the primers used for the RT of miR-181a and U6, and for the qPCR analysis, are summarized in Table I .
Cell viability assay. Cell viability was measured using a CellTiter-Glo Luminescent Cell Viability Assay kit (Promega Corporation, Madison, WI, USA) according to the manufacturer's instructions. For the assay, 1x10 4 K562-miR-181a and the control K562-EGFP cells, which had been treated with DMEM containing 0.05, 0.1, 0.2 or 0.4 µM imatinib (Selleck Chemicals, Houston, TX, USA) for 72 h prior to the assay, were employed.
Cell apoptosis assa y. For t he apoptosis assay, 5x10 5 K562-miR-181a and K562-EGFP cells were exposed to 0.3 µM imatinib for 24 h, and subsequently, cell apoptosis was detected with an apoptosis kit (BD Biosciences). The cells were collected, washed and resuspended in binding buffer at a density of 1x10 6 cells/ml. Next, 1x10 5 cells were incubated for 15 min with 5 µl phycoerythrin (PE)-Annexin V and 5 µl 7-aminoactinomycin D at room temperature in the dark, and analyzed using a FACSCanto II flow cytometer (BD Biosciences) 1 h later.
Cell proliferation assay. For the cell proliferation assay, 2x10 5 cells were cultured in a 10-cm dish and incubated in complete medium at 37˚C in the presence of 5% CO 2 . The cells were counted after different time intervals using a cell counting chamber, and the cell growth curve was represented according to the logarithmic value of the number of cells measured at the different time-points.
Cell cycle analysis. To analyze the cell cycle, the K562 cells were harvested, washed twice with phosphate-buffered saline (PBS), and fixed in 75% ethanol at 4˚C overnight. Following 2 washes with ice-cold PBS, the cells were incubated with RNaseA (20 µg/ml) at 37˚C for 30 min, and stained with propidium iodide (PI) (0.5 mg/ml) at 4˚C for 30 min. The cells were then washed with PBS containing 1% bovine serum albumin, and resuspended in 500 µl PBS. Flow cytometric data of PI were acquired from ~10 5 cells using a flow cytometer.
Induction and determination of K562 cell differentiation.
The K562 cells were seeded at a density of 5x10 5 cells/ml in DMEM, supplemented with 50 µM hemin (Sigma-Aldrich, St. Louis, USA) to induce erythroid differentiation or 25 µM TPA (Sigma-Aldrich) for megakaryocytic differentiation. The erythroid differentiation of K562 cells were analyzed based on the expression of γ-globin and CD235a using RT-qPCR or 20 µg/ml benzidine staining (Sigma-Aldrich). The megakaryocytic differentiation of K562 cells was measured by determining the expression of CD41 and CD61 using RT-qPCR. Primers used for RT-qPCR are listed in Table I .
Statistical analysis. Data were presented as the mean ± standard deviation and subjected to a one-way analysis of variance (ANOVA). A Student's t-test was used to compare the relative expression of target genes and the ANOVA analysis was used to test the effect of miR-181a on the chemotherapeutic sensitivity of K562 cells to imatinib. P<0.05 was considered to indicate statistically significance. SPSS software version 10.0 for windows (SPSS, Inc., Chicago, IL, USA) was used to conduct the statistical analyses.
Results
Reduced expression of miR-181a in the CML patient and K562 cell line. In order to detect potential alterations in the expression pattern of miR-181a in CML, the expression levels of miR-181a were measured by RT-qPCR in 1 patient with CML and in the CML K562 cell line, and compared with the expression levels of miR-181a in 3 healthy volunteers used as controls. The results indicated that the expression levels of miR-181a were significantly reduced in the patient with CML and in the CML K562 cells (Fig. 1) .
Overexpression of miR-181a enhances the chemotherapy sensitivity of K562 cells to imatinib. To investigate the potential Table I . Primers used in the present study.
Primer
Sequence ( levels of miR-181a were 8.3-fold higher in the K562 cells overexpressing miR-181a compared with the control cells (P<0.05; Fig. 2A) . Next, the K562 cells overexpressing miR-181a and the control cells were treated for 72 h with different concentrations of imatinib (0.025, 0.05, 0.1, 0.2, 0.4, 0.6 or 0.8 µM), prior to be subjected to RT-qPCR analysis. The results revealed that the half maximal inhibitory concentration of imatinib in the K562-miR-181a cells was significantly lower than that in the control cells (0.23 vs. 0.29 µM, respectively; P<0.023; Fig. 2B ), which suggested that the overexpression of miR-181a in K562 cells enhances the sensitivity of these CML cells to imatinib.
miR-181a promotes the apoptosis of K562 cells induced by imatinib.
To identify the potential mechanism mediating the increased sensitivity of K562 cells overexpressing miR-181a to the chemotherapeutic agent imatinib, the effect of miR-181a on the apoptosis of the K562 cells was evaluated.
Compared with the control cells, the apoptosis induced by imatinib was increased by ~10% in the K562-miR-181a cells ( Fig. 3A and B) , which suggested that miR-181a promotes the apoptosis of K562 cells.
miR-181a inhibits the growth of K562 cells by repressing the G 1 /S phase transition of the cell cycle.
The effect of miR-181a on the proliferation of the K562 cells was assessed via a cell growth curve assay. The results indicated that the overexpression of miR-181a significantly inhibited the proliferation of K562 cells (Fig. 4A) . To evaluate the effect of miR-181a on the cell cycle, the number of K562-miR-181a cells that were arrested at the G 1 and S phases of the cell cycle was measured at different time-points and compared with the number of K562-EGFP cells arrested at these phases. Pre-synchronization of the K562-miR-181a and K562-EGFP cells was achieved by serum starvation. The results demonstrated that the percentage of K562-miR-181a cells arrested at G 1 was higher than the percentage of K562-EGFP cells, while the opposite was observed for the percentage of cells arrested at the S phase of the cell cycle (Fig. 4B) . These findings suggested that the overexpression of miR-181a inhibits the G 1 /S phase transition of the cell cycle in K562 cells.
Overexpression of miR-181a promotes the differentiation of K562 cells.
The differentiation status of leukemia cells usually affects the sensitivity of their response to chemotherapy treatment (15) . In addition, the chemotherapeutic agents used for the treatment of leukemia may promote the differentiation of leukemia cells (16) . Previous studies have demonstrated that bipotent K562 cells may be induced to undergo erythroid and megakaryocytic differentiation by hemin and TPA, respectively (10) . In the present study, the effect of miR-181a on the erythroid and megakaryocytic differentiation of K562 cells was investigated.
The erythroid differentiation of the K562 cells was evaluated by benzidine staining and by the expression levels of CD235a and γ-globin, following induction with hemin. The results indicated that the overexpression of miR-181a in the K562 cells enhanced the expression of CD235a (P<0.05; Fig. 5A ) and γ-globin (P<0.05; Fig. 5B) , and increased the percentage of benzidine-positive cells, from 27% in the K562-EGFP cells to 36.5% in the K562-miR-181a cells (P<0.05; Fig. 5C and D) . These findings suggested that miR-181a promotes the erythroid differentiation of K562 cells.
The megakaryocytic differentiation of the K562 cells was evaluated according to the expression levels of CD41 and CD61 following treatment with TPA. The results indicated that the overexpression of miR-181a promoted the expression of CD41 and CD61 (P<0.05 vs. control cells; Fig. 6A and B) , which suggested that miR-181a promotes the megakaryocytic differentiation of K562 cells. Taken together, these results demonstrated that miR-181a promotes cell differentiation in CML K562 cells.
Discussion
Previous studies have suggested that miR-181 may act as a tumor suppressor or as an oncogene, depending on the cancer type. The downregulation of miR-181 has been observed to be critical for the development of B-CLL, and its loss has also been associated with adverse prognosis in patients with cytogenetically abnormal AML (12, 14) . The downregulation of miR-181, due to the activation of nuclear factor-κB, has been reported to contribute to a poor clinical outcome in patients with estrogen receptor -positive breast tumors by enhancing stem cell-like properties in these tumor cells (17) . Similarly, low expression levels of miR-181a have been associated with the poor differentiation of colorectal cancer (CRC) cells, and with decreased survival times of patients with CRC (18) . In a model of human glioma, miR-181a and miR-181b induced cell apoptosis and inhibited cell proliferation and invasion (19) . These results suggested that miR-181 is a tumor suppressor. However, in hepatic carcinoma, members of the miR-181 family were observed to be significantly upregulated, and the overexpression of miR-181 promoted hepatocarcinogenesis and the migration of cancer cells (20, 21) . Furthermore, miR-181 was also observed to stimulate progression in breast cancer (22, 23) . Therefore, these results indicate that miR-181 also acts as an oncogene in certain types of cancer. Therefore, the best of our knowledge, the present study investigated the function of miR-181a in CML for the first time.
Previous studies have demonstrated that miR-181 sensitizes malignant human glioma cells to radiation, which suggests that miR-181a may affect the sensitivity to chemotherapy treatment of certain types of cancer (24) . To evaluate the effect of miR-181a in the treatment of CML, the effect of miR-181a on the chemotherapeutic sensitivity of CML K562 cells to imatinib was investigated, and the results indicated that the overexpression of miR-181a in the K562 cells increased the chemotherapeutic sensitivity of these cells to imatinib. These findings are in agreement with a previous study, which reported that miR-181c was downregulated in imatinib-resistant CML (25) . In order to identify the potential mechanism by which miR-181a sensitizes K562 cells to the chemotherapeutic effects of imatinib, the impact of miR-181a on the apoptosis and proliferation of K562 cells was evaluated. The results demonstrated that miR-181a promoted the apoptosis of K562 cells induced by imatinib and inhibited the proliferation of K562 cells by blocking the transition from the G 1 to S phase of the cell cycle. Previous studies have reported that miR-181 targets B-cell lymphoma 2 (Bcl-2), an anti-apoptotic gene frequently overexpressed in cancer, which contributes to the cell apoptosis induced by miR-181 (24, 26) . Therefore, targeting Bcl-2 may be an additional mechanism by which miR-181a promotes the imatinib-induced apoptosis of K562 cells.
miR-181 has been previously demonstrated to promote cell differentiation. miR-181 has been observed to facilitate the differentiation and development of immunity cells (including natural killer cells, and B and T lymphocytes), and to promote the differentiation of mammalian myoblasts, human embryonic stem cells and osteoblasts, by targeting different genes (3) (4) (5) (6) (7) (8) (27) (28) (29) . Since the differentiation status of the tumor cells usually affects their sensitivity to chemotherapy, the effect of miR-181a on the differentiation of K562 cells was evaluated in the present study. The results indicated that the overexpression of miR-181a promoted the erythroid and megakaryocytic differentiation of the K562 cells, which may also contribute to the enhanced chemotherapeutic sensitivity exhibited by these cells towards the chemotherapeutic agent imatinib.
In summary, the present study demonstrated that the overexpression of miR-181a in CML K562 cells enhances the chemotherapeutic sensitivity of these cells to imatinib. These effects may be due to the capacity of miR-181a to inhibit cell growth, and/or to induce apoptosis and differentiation in CML cells.
